GLP-1RA与SGLT2i在2型糖尿病合并CKD美国退伍军人中的肾脏疗效比较
本研究在美国退伍军人健康管理数据库中比较了年龄≥65岁、2型糖尿病合并CKD 3-4期患者启动GLP-1RA或SGLT2i后的肾脏结局。经倾向评分匹配加权控制100余项协变量后,中位随访11个月,主要复合终点(ESKD、 sustained 40%肾功能下降或全因死亡)风险两组相似,但GLP-1RA组肾功能持续下降和ESKD风险较高。
要点
- 老年2型糖尿病合并CKD 3-4期患者中,GLP-1RA与SGLT2i的主要复合肾脏与生存终点风险相似。
- GLP-1RA组肾功能持续下降和ESKD风险高于SGLT2i组,绝对差异在更晚期CKD中更大。
- 结果在CKD分期、心血管病史、BMI和HbA1c亚组中一致。
核心结论
- 在老年2型糖尿病合并CKD 3-4期退伍军人中,GLP-1RA与SGLT2i的整体肾脏和生存结局大致相当,但SGLT2i在肾功能下降和ESKD风险方面可能更具优势。
研究设计与样本
- 基于美国退伍军人健康管理数据库的回顾性队列研究,纳入2016-2025年年龄≥65岁、2型糖尿病合并CKD 3-4期(eGFR 15至<60 mL/min/1.73 m2)启动GLP-1RA或SGLT2i者。
- 共识别28,365例GLP-1RA启动者和78,354例SGLT2i启动者,平均(SD)年龄分别为74(6)岁和76(6)岁。
- 采用倾向评分匹配加权控制100余项协变量,中位随访11个月。
主要发现
- 主要复合终点(ESKD、 sustained 40%肾功能下降或全因死亡)加权风险两组相似:HR(95%CI)1.00(0.94, 1.07);每1000人年率差(95%CI)0.0002(-0.0037, 0.0042)。
- 主要终点相似主要归因于全因死亡风险相似。
- GLP-1RA组 vs SGLT2i组的次要结局风险较高,包括肾功能持续下降和ESKD风险较高。
- 结果在基线CKD分期、心血管病史、BMI和HbA1c水平变化中一致。
- 更晚期CKD患者中,主要肾脏事件和ESKD的绝对率差更大。
临床怎么用
- 对于老年2型糖尿病合并CKD 3-4期患者,GLP-1RA与SGLT2i均可考虑用于肾脏和生存保护。
- 若优先关注降低肾功能下降和ESKD风险,SGLT2i可能更具优势,尤其在更晚期CKD患者中。
局限性
- 观察性设计可能残留混杂。
- 中位随访仅11个月,长期结局需进一步验证。
- 研究人群为美国退伍军人,外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To address limited comparative evidence in older, clinically complex patients with type 2 diabetes and moderate-to-advanced chronic kidney disease (CKD), we compared nephroprotective outcomes after GLP-1RA versus SGLT2i initiation among US Veterans aged ≥65 years with type 2 diabetes and CKD stages 3-4 during 2016-2025. METHODS: Within the U.S. Veterans Health Administration database, we identified individuals with type 2 diabetes and CKD stage 3-4 (eGFR 15 to <60 mL/min/1.73 m2) initiating GLP-1RA vs SGLT2i. GLP-1RA formulations approved for weight loss were excluded. The primary outcome was a composite of ESKD, sustained 40% decline in kidney function, or all-cause mortality, with individual components being secondary outcomes. After controlling for >100 covariates including comorbidities, medications, clinical parameters, and laboratory results using propensity score matching weights, we estimated hazard ratios and rate differences. Analyses were stratified by CKD stages, HbA1c, and body mass index. RESULTS: We identified 28,365 GLP-1RA and 78,354 SGLT2i initiators [mean (SD) age: 74 (6) years vs. 76 (6) years]. Over a median follow-up of 11 months, the weighted risks for the primary outcome were similar between treatment groups [HR (95% CI): 1.00 (0.94, 1.07); RD per 1,000 person-years (95% CI): 0.0002 (-0.0037, 0.0042)], mainly attributed to the similar risk for all-cause mortality. The risks of the secondary outcomes were higher in GLP-1RA vs. SGLT2i initiators, but higher risks for sustained kidney function decline and ESKD. Findings were consistent across variations in baseline CKD stage, history of CVD, BMI, and HbA1c level. Absolute rate differences for major kidney disease events and ESKD were larger in patients with more advanced CKD stages. CONCLUSIONS: These findings suggest broadly comparable overall kidney and survival outcomes, with potential advantages of SGLT2is for the risks of kidney function decline and incident ESKD across metabolic subgroups in this older adult cohort.
引用
- Htoo PT, Patorno E, Ortega-Montiel J, et al. Comparative Renal Effectiveness of GLP-1RA and SGLT2i in US Veterans with Type 2 Diabetes and CKD. Clin J Am Soc Nephrol. 2026. PMID: 42809365. doi:10.2215/CJN.0000001244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。